This exciting paper presents a chip-based tumor-mimetic platform incorporating a 3D in vitro breast cancer model with a tumor-mimetic microvascular network, replicating the pathophysiological architecture of native vascularized breast tumors.
Murat Cirit – Director of Systems Pharmacology, Translational Center of Tissue Chip Technologies (TC²T) at MIT – discusses how computational models such as quantitative systems pharmacology (QSP) can be applied to enhance the design and development of advanced in vitro platforms.
“Our vision is to generate physiologically relevant information with the use of the all human 3D models, which can be translated to human outcomes”
Joining as a workshop leader this year, he said:
“I am looking forward to gaining more insight into academic developments and how they are pushing forward our research and translational approach, while learning the industrial needs from many leaders in this MPS field.”
Contains the following presentations from 3D Tissue Models 2016:
1) Creating the Environment to Drive Innovation: The Roadmap to Acceptance
2) Use of 3D Tissue Models for Pre-Animal Screening and to Improve Clinical Translation
Read about Organovo’s journey and the rise of 3D Bioprinting technology, the remaining challenges in shifting the paradigm of drug development as well the next key focus areas for them.